The author wishes to clarify that in the development programme of RTP801i, the involvement of Silence Therapeutics was limited to licensing its RNAi technology to Quark Pharmaceuticals. In September 2006, Quark granted Pfizer an exclusive worldwide license to develop and commercialize RTP801i for both ophthalmic and non-ophthalmic indications.
Additional information
The online version of the original article can be found at 10.1038/nrd2443
Rights and permissions
About this article
Cite this article
Melnikova, I. Erratum: RNA-based therapies. Nat Rev Drug Discov 7, 184 (2008). https://doi.org/10.1038/nrd2511
Issue Date:
DOI: https://doi.org/10.1038/nrd2511
